BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Shi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl. 2011;17:866-874. [PMID: 21542129 DOI: 10.1002/lt.22325] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
2 Lyra-gonzález I, Flores-fong LE, González-garcía I, Medina-preciado D, Armendáriz-borunda J. Adenoviral gene therapy in hepatocellular carcinoma: a review. Hepatol Int 2013;7:48-58. [DOI: 10.1007/s12072-012-9367-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Dai X, Ding J, Zhang R, Ren J, Ma CC, Wu G. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. International Journal of Radiation Biology 2013;89:724-31. [DOI: 10.3109/09553002.2013.791405] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
4 Liu XF, Long HJ, Miao XY, Liu GL, Yao HL. Fisetin inhibits liver cancer growth in a mouse model: Relation to dopamine receptor. Oncol Rep 2017;38:53-62. [PMID: 28560391 DOI: 10.3892/or.2017.5676] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
5 Guillot C, Hall J, Herceg Z, Merle P, Chemin I. Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy. Clin Res Hepatol Gastroenterol 2014;38:137-42. [PMID: 23953496 DOI: 10.1016/j.clinre.2013.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
7 Tang B, Du J, Wang J, Tan G, Gao Z, Wang Z, Wang L. Alpinetin suppresses proliferation of human hepatoma cells by the activation of MKK7 and elevates sensitization to cis-diammined dichloridoplatium. Oncol Rep 2012;27:1090-6. [PMID: 22159816 DOI: 10.3892/or.2011.1580] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
8 Rajendran P, Li F, Manu KA, Shanmugam MK, Loo SY, Kumar AP, Sethi G. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol. 2011;163:283-298. [PMID: 21198544 DOI: 10.1111/j.1476-5381.2010.01187.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 8.5] [Reference Citation Analysis]
9 Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol 2014; 20(43): 16167-16177 [PMID: 25473170 DOI: 10.3748/wjg.v20.i43.16167] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
10 Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010; 16(34): 4281-4290 [PMID: 20818811 DOI: 10.3748/wjg.v16.i34.4281] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
11 Lian H, Tang J, Sun YC, Zhang S. Mechanisms underlying vesicular stomatitis virus-induced apoptosis of HepG2 cells in vitroShijie Huaren Xiaohua Zazhi 2011; 19(7): 667-673 [DOI: 10.11569/wcjd.v19.i7.667] [Reference Citation Analysis]
12 Lawless MW, O’Byrne KJ, Gray SG. Targeting oxidative stress in cancer. Expert Opin Ther Targets. 2010;14:1225-1245. [PMID: 20942747 DOI: 10.1517/14728222.2010.526933] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
13 Huo L, Guo J, Dang Y, Lv J, Zheng Y, Li F, Xie Q, Chen X. Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions. Theranostics 2015;5:371-7. [PMID: 25699097 DOI: 10.7150/thno.10760] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
14 Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget. 2015;6:18613-18630. [PMID: 26164082 DOI: 10.18632/oncotarget.4317] [Cited by in Crossref: 44] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
15 Gao F, Jing P, Liu J, Lu Y, Zhang P, Han W, Liu G, Ru N, Cui G, Sun C, Che Y, Zhang H, Hu Q, Wang HY, Wu Y, Guan C, Fu Q, Ma Z, Yu B. Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. J Hepatocell Carcinoma 2015;2:57-68. [PMID: 27508195 DOI: 10.2147/JHC.S80756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg 2010;200:659-64. [PMID: 21056149 DOI: 10.1016/j.amjsurg.2010.07.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, Kwon JH. Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging. 2012;46:102-110. [PMID: 24900042 DOI: 10.1007/s13139-012-0138-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
18 Yang S, Liu Y, Feng X, Wang X, Wu M, Gong L, Shu B, Lu Q, Dong J. HBx acts as an oncogene and promotes the invasion and metastasis of hepatocellular carcinoma both in vivo and vitro. Dig Liver Dis 2021;53:360-6. [PMID: 33153927 DOI: 10.1016/j.dld.2020.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Liu TA, Jan YJ, Ko BS, Chen SC, Liang SM, Hung YL, Hsu C, Shen TL, Lee YM, Chen PF, Wang J, Shyue SK, Liou JY. Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol 2011;179:2698-708. [PMID: 21967815 DOI: 10.1016/j.ajpath.2011.08.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
20 Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
21 Lin JJ, Wang RY, Chen JC, Chiu CC, Liao MH, Wu YJ. Cytotoxicity of 11-epi-Sinulariolide Acetate Isolated from Cultured Soft Corals on HA22T Cells through the Endoplasmic Reticulum Stress Pathway and Mitochondrial Dysfunction. Int J Mol Sci 2016;17:E1787. [PMID: 27801783 DOI: 10.3390/ijms17111787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
22 Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 2017;37:2215-26. [PMID: 28350084 DOI: 10.3892/or.2017.5494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
23 Fassina A. 'The map is not the territory': FNA the map and liver the territory. Cytopathology 2011;22:285-6. [PMID: 21923726 DOI: 10.1111/j.1365-2303.2011.00928.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Wang XD, Yang RJ, Cao XC, Tan J, Li B. Dose delivery estimated by bremsstrahlung imaging and partition model correlated with response following intra-arterial radioembolization with 32P-glass microspheres for the treatment of hepatocellular carcinoma. J Gastrointest Surg. 2010;14:858-866. [PMID: 20224983 DOI: 10.1007/s11605-010-1180-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Braillon A. Hepatocellular carcinoma and evidence-based surgery. World J Gastroenterol 2009; 15(42): 5371-5371 [PMID: 19908350 DOI: 10.3748/wjg.15.5371] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
26 Meng XQ, Zhang W, Zhang F, Yin SY, Xie HY, Zhou L, Zheng SS. Solanine-induced reactive oxygen species inhibit the growth of human hepatocellular carcinoma HepG2 cells. Oncol Lett 2016;11:2145-51. [PMID: 26998139 DOI: 10.3892/ol.2016.4167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Kokabi N, Duszak R, Xing M, Howard DH, Applegate KE, Camacho JC, Kim HS. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. Future Oncology 2017;13:2021-33. [DOI: 10.2217/fon-2017-0116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010;292:197-207. [PMID: 20053498 DOI: 10.1016/j.canlet.2009.12.003] [Cited by in Crossref: 118] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
29 Chou CT, Chen YL, Su WW, Wu HK, Chen RC. Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging. J Magn Reson Imaging. 2010;32:895-902. [PMID: 20882620 DOI: 10.1002/jmri.22316] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
30 Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer 2017;123:1073. [PMID: 28085185 DOI: 10.1002/cncr.30550] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Li C, Wu M, Zong G, Wan C, Liu Q, Zhou H, Hua L, Chen Y, Chen X, Lu C. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci 2017;62:133-42. [PMID: 27921263 DOI: 10.1007/s10620-016-4365-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Tao J, Ji J, Li X, Ding N, Wu H, Liu Y, Wang XW, Calvisi DF, Song G, Chen X. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget 2015;6:6977-88. [PMID: 25762642 DOI: 10.18632/oncotarget.3166] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
33 Zhang Q, Bai XL, Chen W, Ma T, Liu H, Zhang Y, Hu XJ, Liang TB; Cochrane Hepato-Biliary Group. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010897] [Reference Citation Analysis]
34 Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011;100:22-9. [PMID: 21482502 DOI: 10.1177/145749691110000105] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
35 Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci 2018;19:E4070. [PMID: 30562917 DOI: 10.3390/ijms19124070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
36 Wang M, Wei K, Qian B, Feiler S, Lemekhova A, Büchler MW, Hoffmann K. HSP70-eIF4G Interaction Promotes Protein Synthesis and Cell Proliferation in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2262. [PMID: 32823513 DOI: 10.3390/cancers12082262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioglu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol 2011; 17(37): 4206-4212 [PMID: 22072852 DOI: 10.3748/wjg.v17.i37.4206] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
38 Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/Leucovorin vs doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501-3508. [PMID: 23980077 DOI: 10.1200/jco.2012.44.5643] [Cited by in Crossref: 218] [Cited by in F6Publishing: 138] [Article Influence: 24.2] [Reference Citation Analysis]
39 Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768. [PMID: 23947969 DOI: 10.1016/j.jval.2013.03.1630] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
40 Fehér J, Lengyel G. [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. Orv Hetil 2010;151:933-40. [PMID: 20494888 DOI: 10.1556/OH.2010.28900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
41 Lee NP, Poon RT, Shek FH, Ng IO, Luk JM. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta. 2010;1806:138-145. [PMID: 20580775 DOI: 10.1016/j.bbcan.2010.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
42 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
43 Wen Y, Zhao RQ, Zhang YK, Gupta P, Fu LX, Tang AZ, Liu BM, Chen ZS, Yang DH, Liang G. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. Oncotarget 2017;8:29760-70. [PMID: 28423656 DOI: 10.18632/oncotarget.15964] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
44 Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, Kumar AP, Senapati P, Behera AK, Hui KM, Basha J, Natesh N, Luk JM, Kundu TK. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 2014;13:66. [PMID: 24655440 DOI: 10.1186/1476-4598-13-66] [Cited by in Crossref: 115] [Cited by in F6Publishing: 112] [Article Influence: 14.4] [Reference Citation Analysis]
45 Faber W, Seehofer D, Neuhaus P, Stockmann M, Denecke T, Kalmuk S, Warnick P, Bahra M. Repeated liver resection for recurrent hepatocellular carcinoma: Recurrent hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2011;26:1189-94. [DOI: 10.1111/j.1440-1746.2011.06721.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
46 Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530-549. [PMID: 23921081 DOI: 10.1016/j.critrevonc.2013.07.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
47 Xiao WH, Sanren GW, Zhu JH, Li QW, Kang HR, Wang RL, Song LP, Ye M. Effect of 5-Aza-2’-deoxycytidine on immune-associated proteins in exosomes from hepatoma. World J Gastroenterol 2010; 16(19): 2371-2377 [PMID: 20480522 DOI: 10.3748/wjg.v16.i19.2371] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
48 Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010; 2(5): 171-174 [PMID: 21160991 DOI: 10.4254/wjh.v2.i5.171] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
49 Chau GY. Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome. World J Gastroenterol 2014; 20(35): 12473-12484 [PMID: 25253947 DOI: 10.3748/wjg.v20.i35.12473] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
50 Iancu C, Mocan L, Bele C, Orza AI, Tabaran FA, Catoi C, Stiufiuc R, Stir A, Matea C, Iancu D, Agoston-Coldea L, Zaharie F, Mocan T. Enhanced laser thermal ablation for the in vitro treatment of liver cancer by specific delivery of multiwalled carbon nanotubes functionalized with human serum albumin. Int J Nanomedicine 2011;6:129-41. [PMID: 21289990 DOI: 10.2147/IJN.S15841] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
51 Zhao F, Zhao J, Song L, Zhang Y, Guo Z, Yang K. The induction of apoptosis and autophagy in human hepatoma SMMC-7721 cells by combined treatment with vitamin C and polysaccharides extracted from Grifola frondosa. Apoptosis 2017;22:1461-72. [DOI: 10.1007/s10495-017-1421-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
52 Chen X, Xiao E, Shu D, Yang C, Liang B, He Z, Bian D. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol. 2014;26:109-113. [PMID: 24284371 DOI: 10.1097/meg.0b013e328363716e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
53 Qian P, Zhang Y, Zhou Z, Liu J, Yue S, Guo X, Sun L, Lv X, Chen J. Artesunate enhances γδ T-cell-mediated antitumor activity through augmenting γδ T-cell function and reversing immune escape of HepG2 cells. Immunopharmacology and Immunotoxicology 2018;40:107-16. [DOI: 10.1080/08923973.2017.1386212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
54 Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging. 2011;36:300-314. [PMID: 21279353 DOI: 10.1007/s00261-011-9683-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
55 Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opin Drug Metab Toxicol 2011;7:1535-46. [PMID: 22032293 DOI: 10.1517/17425255.2011.631911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
56 He L, Gong HX, Li XP, Wang YD, Li Y, Huang JJ, Xie D, Kung HF, Peng Y. Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice. Oncol Lett 2013;6:748-52. [PMID: 24137404 DOI: 10.3892/ol.2013.1470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
57 Zhang Z, Yin J, Zhang C, Liang N, Bai N, Chang A, Liu Y, Li Z, Tan X, Li N. Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma. Cancer Biol Ther. 2012;13:435-442. [PMID: 22338651 DOI: 10.4161/cbt.19295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
58 Hazin H, Dosik D. Personalized Chemotherapy for Hepatocellular Carcinoma. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 53-60. [DOI: 10.1007/978-3-319-12166-6_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Scheele JS, Harder J, Stankovic Z, Räpple D, Dorn A, Spangenberg HC, Blum HE. Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. J Med Case Rep 2011;5:478. [PMID: 21943068 DOI: 10.1186/1752-1947-5-478] [Reference Citation Analysis]
60 Teixeira AC, Mente ED, Castro-e-Silva O, Sankarankutty AK, Cantão CA, Souza FF, Abud D, Muglia V, Elias-Junior J, Martinelli AL. Treatment of hepatocellular carcinoma with liver transplantation: a single-center experience from Brazil. Transplant Proc 2010;42:502-4. [PMID: 20304177 DOI: 10.1016/j.transproceed.2010.01.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
61 Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, Luo Y, Dong JH. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10:143-150. [PMID: 21459720 DOI: 10.1016/s1499-3872(11)60023-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
62 Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3035-3040 [PMID: 25780303 DOI: 10.3748/wjg.v21.i10.3035] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
63 Zhou Z, Lu X, Zhu P, Zhu W, Mu X, Qu R, Li M. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells. Biochemical and Biophysical Research Communications 2012;420:336-42. [DOI: 10.1016/j.bbrc.2012.02.160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
64 Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017;123:751-8. [PMID: 27911488 DOI: 10.1002/cncr.30462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
65 Taghiyev A, Sun D, Gao ZM, Liang R, Wang L. Embelin-induced apoptosis of HepG2 human hepatocellular carcinoma cells and blockade of HepG2 cells in the G2/M phase via the mitochondrial pathway. Exp Ther Med 2012;4:649-54. [PMID: 23170120 DOI: 10.3892/etm.2012.637] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
66 Azab SS, Abdel-daim M, Eldahshan OA. Phytochemical, cytotoxic, hepatoprotective and antioxidant properties of Delonix regia leaves extract. Med Chem Res 2013;22:4269-77. [DOI: 10.1007/s00044-012-0420-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
67 Abei M, Okumura T, Fukuda K, Hashimoto T, Araki M, Ishige K, Hyodo I, Kanemoto A, Numajiri H, Mizumoto M. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol. 2013;8:239. [PMID: 24131485 DOI: 10.1186/1748-717x-8-239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
68 Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015;30:1167-1174. [PMID: 25675849 DOI: 10.1111/jgh.12920] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
69 Lai XD, Chen XH, Xu HB, Liu YR, Ma NF. Correlations of EIF-5A2 protein expression with VEGF expression and microvessel density in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 137-142 [DOI: 10.11569/wcjd.v18.i2.137] [Reference Citation Analysis]
70 Cai J, Xiong Q, Jiang X, Zhou S, Liu T. RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Experimental Cell Research 2019;374:152-61. [DOI: 10.1016/j.yexcr.2018.11.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
71 Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N, Kanematsu T, Fujioka H. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res. 2012;172:116-122. [PMID: 20855083 DOI: 10.1016/j.jss.2010.07.057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
72 Jan YJ, Ko BS, Liu TA, Wu YM, Liang SM, Chen SC, Wang J, Liou JY. Expression of partitioning defective 3 (Par-3) for predicting extrahepatic metastasis and survival with hepatocellular carcinoma. Int J Mol Sci 2013;14:1684-97. [PMID: 23322019 DOI: 10.3390/ijms14011684] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
73 Neelgundmath M, Dinesh KR, Mohan CD, Li F, Dai X, Siveen KS, Paricharak S, Mason DJ, Fuchs JE, Sethi G, Bender A, Rangappa KS, Kotresh O, Basappa. Novel synthetic coumarins that targets NF-κB in Hepatocellular carcinoma. Bioorganic & Medicinal Chemistry Letters 2015;25:893-7. [DOI: 10.1016/j.bmcl.2014.12.065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
74 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
75 Chien CC, Han MM, Chiu YH, Wang JJ, Chu CC, Hung CY, Sun YM, Yeh NC, Ho CH, Lin CC, Kao HY, Weng SF. Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan. J Cancer 2017;8:9-18. [PMID: 28123593 DOI: 10.7150/jca.16550] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
76 Gao M, Xu H, Zhang C, Liu K, Bao X, Chu Q, He Y, Tian Y. Preparation and characterization of curcumin thermosensitive hydrogels for intratumoral injection treatment. Drug Development and Industrial Pharmacy 2014;40:1557-64. [DOI: 10.3109/03639045.2013.838579] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
77 Ganslmayer M, Zimmermann A, Zopf S, Herold C. Combined inhibitors of angiogenesis and histone deacetylase: Efficacy in rat hepatoma. World J Gastroenterol 2011; 17(31): 3623-3629 [PMID: 21987609 DOI: 10.3748/wjg.v17.i31.3623] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Kokabi N, Camacho JC, Xing M, El-rayes BF, Spivey JR, Knechtle SJ, Kim HS. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis: Phase 2 90 Y Therapy in Infiltrative HCC. Cancer 2015;121:2164-74. [DOI: 10.1002/cncr.29275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
79 Wang ML, Miao F, Tang YH, Zhao XS, Zhong J, Yuan F. Special diaphragm-like strictures of small bowel unrelated to non-steroidal anti-inflammatory drugs. World J Gastroenterol 2011; 17(31): 3596-3604 [PMID: 21987606 DOI: 10.3748/wjg.v17.i31.3596] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
80 Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ. A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. Cancer. 2011;117:2951-2960. [PMID: 21692054 DOI: 10.1002/cncr.25837] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
81 Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J Clin Oncol. 2011;41:69-75. [PMID: 20688778 DOI: 10.1093/jjco/hyq145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
82 Chen WX, Zhang ZG, Ding ZY, Liang HF, Song J, Tan XL, Wu JJ, Li GZ, Zeng Z, Zhang BX, Chen XP. MicroRNA-630 suppresses tumor metastasis through the TGF-β- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget 2016;7:22674-86. [PMID: 26993767 DOI: 10.18632/oncotarget.8047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
83 Roderburg C, Bubenzer J, Spannbauer M, O ND, Mahnken A, Ludde T, Trautwein C, Tischendorf JJ. Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. World J Hepatol 2010; 2(6): 239-242 [PMID: 21161003 DOI: 10.4254/wjh.v2.i6.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
84 Zhou Y, He P, Xie X, Sun C. Knockdown of SUMO1P3 represses tumor growth and invasion and enhances radiosensitivity in hepatocellular carcinoma. Mol Cell Biochem 2019;450:125-34. [PMID: 29905911 DOI: 10.1007/s11010-018-3379-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
85 Bai M, Reynolds NR, Mccorkle R. The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. Pall Supp Care 2013;11:503-22. [DOI: 10.1017/s1478951512001137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
86 Kokabi N, Xing M, Duszak R Jr, Duszak R Jr, Howard DH, Applegate KE, Camacho JC, Kim HS. Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncol 2016;12:183-98. [PMID: 26690268 DOI: 10.2217/fon.15.242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
87 Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL, Yin ZQ, Yan J. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers. Biomed Res Int 2021;2021:2676745. [PMID: 33490265 DOI: 10.1155/2021/2676745] [Reference Citation Analysis]
88 Cheng Y, Yin B, Hou T, Chen T, Ping J. The overexpression of GRASP might inhibit cell proliferation and invasion in hepatocellular carcinoma. J Cell Physiol 2019. [PMID: 30779348 DOI: 10.1002/jcp.28285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
89 Wu YY, Wan LH, Zheng XW, Shao ZJ, Chen J, Chen XJ, Liu LT, Kuang WJ, Tan XS, Zhou LM. Inhibitory effects of β,β-dimethylacrylshikonin on hepatocellular carcinoma in vitro and in vivo. Phytother Res 2012;26:764-71. [PMID: 22109831 DOI: 10.1002/ptr.3623] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
90 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
91 Khandoga A, Drefs M, Schoenberg M, Schiergens T, Frenes K, Op den Winkel M, Trumm C, Angele MK, Guba M, Werner J, Rentsch M. Differential significance of early surgical complications for acute and long-term recurrence-free survival following surgical resection of hepatocellular carcinoma: do comorbidities play a role? Eur J Gastroenterol Hepatol 2017;29:1045-53. [PMID: 28562395 DOI: 10.1097/MEG.0000000000000912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
92 Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, Liu J, Yu S, He S. Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle. Int J Nanomedicine 2016;11:6401-20. [PMID: 27942213 DOI: 10.2147/IJN.S101285] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
93 Lin WH, Yeh SH, Yang WJ, Yeh KH, Fujiwara T, Nii A, Chang SS, Chen PJ. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int J Cancer. 2013;132:1451-1462. [PMID: 22886913 DOI: 10.1002/ijc.27770] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
94 Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int 2011;31:810-6. [PMID: 21645211 DOI: 10.1111/j.1478-3231.2011.02511.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
95 Tang B, Hu Z, Li Y, Yuan S, Wang Z, Yu S, He S. Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU. Mol Med Rep 2016;13:59-66. [PMID: 26549838 DOI: 10.3892/mmr.2015.4511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Chou CT, Wu WP, Chen CB, Su WW, Chen RC, Chen YL. The utility of gadoxetic acid-enhanced MR imaging to characterize atypical cirrhotic nodules detected on dynamic CT images. PLoS One 2014;9:e107869. [PMID: 25310817 DOI: 10.1371/journal.pone.0107869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]